Welcome to visit Hefei Kangchuntang Pharmaceutical Co., Ltd!

中文版 中文版  |   英文版 英文版
Manager
OA Login

Contact Us

Hefei Kangchuntang Pharmaceutical Co., Ltd.
Address: No.13, Branch Road, Biomedical Park, High-tech Zone, Hefei City, Anhui Province
Telephone:86551-63830999/63673366

Leaders from the Hefei Municipal Health Commission and Hefei Municipal Bureau of Economy and Information visited the company for investigation and guidance

2020-12-24 11:04

Leaders from Hefei Municipal Health Commission and Hefei Municipal Bureau of Economy and Information visited the company for investigation and guidance.

National Medical Products Administration Center for Drug Evaluation's Announcement on the Release of the 'Technical Guidelines for Pharmacological Research at Each Stage of the Development of New Traditional Chinese Medicines (Trial)' (No. 37, 2020)

2020-11-06 09:40

Under the guidance of the National Medical Products Administration (NMPA), the Center for Drug Evaluation (CDE) has formulated the "Technical Guidelines for Pharmaceutical Research at Various Stages of New Traditional Chinese Medicine Drug Research (Trial Implementation)" (see attachment). In accordance with the requirements of the "Notice on the Issuance of the Release Procedure for Pharmaceutical Technical Guidelines" (Yaojianzongyao Guan [2020] No. 9) issued by the Comprehensive Department of the NMPA, and after review and approval by the NMPA, these guidelines are hereby released and shall come into effect from the date of release.

Notice of the National Administration of Traditional Chinese Medicine on Issuing the Implementation Plan for the Support Program of Innovative Teams and Talents in Traditional Chinese Medicine

2020-11-06 09:37

To implement the Opinions of the Central Committee of the Communist Party of China and the State Council on Promoting the Inheritance and Innovation Development of Traditional Chinese Medicine, promote the construction of multidisciplinary cross-innovation teams in Traditional Chinese Medicine, and cultivate a group of young and middle-aged multidisciplinary cross-innovation talents, our bureau has decided to launch the Traditional Chinese Medicine Innovation Team and Talent Support Program.

Notice on Issuing the National Influenza Prevention and Control Work Plan (2020 Edition)

2020-10-09 10:45

To further improve the prevention and control of influenza during the 2020-2021 influenza season, the National Joint Prevention and Control Mechanism of the State Council for the Novel Coronavirus Pneumonia Epidemic has formulated the National Influenza Prevention and Control Work Plan (2020 Edition). This is now issued to you, please organize and implement it seriously. If you have any suggestions during the implementation process, please promptly feedback to the mechanism's comprehensive group.

Notice from the Center for Drug Evaluation of the National Medical Products Administration on the Release of the 'Technical Guiding Principles (Trial) on Real-World Research Supporting Children's Drug R&D and Review'

2020-09-04 14:40

Considering the actual needs of children's drug research and development and drug registration in our country, and to help enterprises better understand the application of the "Guiding Principles for Drug Research and Development and Review Supported by Real-World Evidence (Trial Implementation)" in children's drug research and development, under the deployment of the National Medical Products Administration, the Center for Drug Evaluation organized the formulation of the "Technical Guiding Principles for Real-World Research Supporting Children's Drug Research and Development and Review (Trial Implementation)" (see Appendix). In accordance with the requirements of the "Notice on Issuing the Procedures for Issuing Drug Technical Guiding Principles" (Pharmaceutical Supervision and Administration [2020] No. 9) issued by the Comprehensive Department of the National Medical Products Administration, and with the approval of the National Medical Products Administration, this is now issued and shall come into force from the date of its issuance.

Notice on Issuing Technical Specifications for COVID-19 Nucleic Acid 10-in-1 Mixed Sample Testing

2020-08-31 15:27

Joint Prevention and Control Mechanisms (Leading Groups, Command Headquarters) of all provinces, autonomous regions, municipalities directly under the Central Government, and the Xinjiang Production and Construction Corps for COVID-19: In order to guide local areas in carrying out COVID-19 mixed sample testing, further improve the capacity and efficiency of COVID-19 nucleic acid testing, implement the “four early” requirements, and effectively meet the needs of normalized epidemic prevention and control, we have developed the “Technical Specifications for COVID-19 Nucleic Acid 10-in-1 Mixed Sample Testing”.

People's Daily: Awakening the Sleeping Classic Prescriptions of Traditional Chinese Medicine

2020-08-19 10:25

On June 2, General Secretary Xi Jinping emphasized at an expert and scholar symposium: "We must strengthen the combing and excavation of the essence of classical medical texts, build a number of scientific research support platforms, reform and improve the review and approval mechanism for traditional Chinese medicine, and promote the research and development and industrial development of new traditional Chinese medicines."

Anhui Provincial Committee and Provincial Government issue "Specific Measures for Promoting the Inheritance and Innovation Development of Traditional Chinese Medicine"

2020-08-19 10:24

Recently, the Anhui Provincial Committee and Provincial Government issued the "Specific Measures for Promoting the Inheritance and Innovation Development of Traditional Chinese Medicine", proposing 23 specific measures to promote the inheritance and innovation development of traditional Chinese medicine in seven aspects: providing TCM services covering the entire population and life cycle, continuously deepening TCM reform, optimizing and strengthening the modern TCM industry, strengthening the quality and safety supervision of TCM, accelerating the construction of TCM talent teams, promoting the inheritance, innovation, and open development of TCM, and ensuring measures.

National Medical Products Administration's Opinions on Further Strengthening the Drug Adverse Reaction Monitoring and Evaluation System and Capacity Building

2020-08-14 14:31

In recent years, significant progress has been made in the monitoring and evaluation of adverse drug reactions, adverse events related to medical devices, adverse reactions to cosmetics, and drug abuse (hereinafter collectively referred to as adverse drug reaction monitoring and evaluation). Regulations have been continuously improved, the monitoring and evaluation system has been gradually established, the quantity and quality of reports have steadily increased, risk control measures have become more mature, and international cooperation has continued to strengthen, providing strong support for drug regulatory work. At the same time, it must be acknowledged that shortcomings remain in China's current drug adverse reaction monitoring and evaluation work. The number of grassroots monitoring and evaluation institutions has decreased, there is a shortage of professional personnel, the monitoring information system is lagging, monitoring and evaluation capabilities urgently need to be improved, and funding is insufficient to meet the needs, which has to some extent affected the improvement of drug safety levels and the protection of public health rights. To fully implement the central government's requirements for strengthening drug safety in the new era, the following opinions are put forward on further strengthening the drug adverse reaction monitoring and evaluation system and capacity building.

Warmly celebrating the 90th anniversary of the establishment of the Chinese Peasants and Workers' Democratic Party, the Hefei High-tech Branch of the CPPCC has launched an investigation and discussion.

2020-08-07 12:03

To celebrate the 90th anniversary of the founding of the Chinese Peasants' and Workers' Democratic Party (CPWDP), on the afternoon of August 6th, Bian Huayu, full-time vice chairman of the Hefei Municipal Committee of the CPWDP, and Wang Juan, director of the Propaganda Department of the Hefei Municipal Committee of the CPWDP, visited the Gaoxin Branch of the CPWDP to conduct research and hold a symposium. Zhang Manzhong, deputy director of the Investment Promotion Bureau of Hefei High-tech Zone and chairman of the Gaoxin Branch of the CPWDP; Liu Guang, propaganda committee member of the Gaoxin Branch of the CPWDP and CEO of Hefei Wisdom Dragon Totem Intellectual Property Co., Ltd.; Kong Zhen, general manager of Hefei Kangchuntang Pharmaceutical Co., Ltd.; and Li Duoshan, chairman of Hefei Lianxin Power Supply Co., Ltd., and other CPWDP members of the Gaoxin Branch participated in the research and symposium.

< 1234...10 >